H

Hyphens Pharma International Ltd
SGX:1J5

Watchlist Manager
Hyphens Pharma International Ltd
SGX:1J5
Watchlist
Price: 0.285 SGD Market Closed
Market Cap: 88.1m SGD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one 1J5 stock under the Base Case scenario is 0.5 SGD. Compared to the current market price of 0.285 SGD, Hyphens Pharma International Ltd is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

1J5 Relative Value
Base Case
0.5 SGD
Undervaluation 43%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

0.5
P/S
P/S
Price to Sales
0.5
vs History
82
vs Industry
84
Median 3Y
0.6
Median 5Y
0.6
Industry
2.4
Forward
0.4
More Details
8.6
P/E
P/E
Price to Earnings
8.6
vs History
77
vs Industry
40
Median 3Y
9.9
Median 5Y
10.1
Industry
20.6
Forward
8.5
More Details
29.4
P/OCF
P/OCF
Price to OCF
29.4
vs History
3
vs Industry
14
Median 3Y
14.3
Median 5Y
14.3
Industry
15.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
12
Median 3Y
10.9
Median 5Y
11.5
Industry
23
More Details
1.3
P/B
P/B
Price to Book Value
1.3
vs History
69
vs Industry
52
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9
More Details
0.4
EV/S
EV/S
Enterprise Value to Sales
0.4
vs History
73
vs Industry
87
Median 3Y
0.4
Median 5Y
0.4
Industry
2.5
Forward
0.4
More Details
1.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.1
vs History
68
vs Industry
83
Median 3Y
1.1
Median 5Y
1.1
Industry
4.9
More Details
4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4
vs History
61
vs Industry
48
Median 3Y
4
Median 5Y
4.3
Industry
12.6
Forward
5.5
More Details
4.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4.8
vs History
61
vs Industry
46
Median 3Y
4.8
Median 5Y
5.3
Industry
15.7
Forward
5.6
More Details
24.4
EV/OCF
EV/OCF
Enterprise Value to OCF
24.4
vs History
3
vs Industry
18
Median 3Y
11.2
Median 5Y
11.2
Industry
14
More Details
136.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
136.8
vs History
3
vs Industry
4
Median 3Y
13
Median 5Y
13
Industry
17.7
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
82
vs Industry
51
Median 3Y
1.3
Median 5Y
1.4
Industry
1.8
More Details

Multiples Across Competitors

1J5 Competitors Multiples
Hyphens Pharma International Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Hyphens Pharma International Ltd
SGX:1J5
88m SGD 0.5 8.6 4 4.8
US
Eli Lilly and Co
NYSE:LLY
769.2B USD 17.2 73.1 42.2 46.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.7B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20.1 13.2 15
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.6 26.2 9.8 11.5
CH
Novartis AG
SIX:NOVN
184.7B CHF 4.2 17.3 10.2 13.7
UK
AstraZeneca PLC
LSE:AZN
166.8B GBP 4 28.6 130.9 197.4
US
Merck & Co Inc
NYSE:MRK
212.2B USD 3.3 12.2 8.7 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
122.8B EUR 1.3 9.7 5.3 6.2
P/E Multiple
Earnings Growth PEG
SG
H
Hyphens Pharma International Ltd
SGX:1J5
Average P/E: 23.6
8.6
13%
0.7
US
Eli Lilly and Co
NYSE:LLY
73.1
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.3
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.2
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.7
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
H
Hyphens Pharma International Ltd
SGX:1J5
Average EV/EBITDA: 395
4
4%
1
US
Eli Lilly and Co
NYSE:LLY
42.2
31%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.3
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
H
Hyphens Pharma International Ltd
SGX:1J5
Average EV/EBIT: 1 698.2
4.8
8%
0.6
US
Eli Lilly and Co
NYSE:LLY
46.6
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
CH
Novartis AG
SIX:NOVN
13.7
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4

See Also

Summary
1J5 intrinsic value, competitors valuation, and company profile.
DCF Valuation
1J5 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
1J5 stock valuation using valuation multiples.
Wall Street Estimates
1J5 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
1J5 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 251,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.